Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.
作者： Y Soini , N Virkajarvi , H Raunio , P Paakko
DOI: 10.1136/JCP.49.6.470
关键词:
摘要: AIMS: (1) To investigate the immunohistochemical expression of multidrug resistance gene (MDR1) product P-glycoprotein in histological samples from 31 hepatocellular carcinomas (HCCs); and (2) to correlate results with cell proliferation, p53 expression, disease-free interval, cumulative patient survival. METHODS: C219 (a monoclonal antibody), CM-1 polyclonal rabbit anti-human antibody) PC10 mouse were used detect P-glycoprotein, proliferating nuclear antigen (PCNA), respectively, by means avidin-biotin peroxidase method. RESULTS: Membrane bound positivity for was observed 20 (65%) HCCs. Cytoplasmic globular also seen some cases. There no significant associations between proliferation (determined PCNA immunoexpression mitotic count), or expression. Patients positive tumours had a shorter interval than those negative tumours, survival time. difference patients who not received chemotherapy, suggesting that chemotherapy (mainly mitomycin-C) did affect these patients. CONCLUSIONS: Expression HCCs is associated As p53, its effect on disease progression seems be independent factors.
core.ac.uk
sci-hub.se 参考文章(15)
Hugh A. Edmondson, Paul E. Steiner, Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies Cancer. ,vol. 7, pp. 462- 503 ,(1954) , 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
Mariko Itsubo, Tomohisa Ishikawa, Gotaro Toda, Mitsugu Tanaka, Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer. ,vol. 73, pp. 298- 303 ,(1994) , 10.1002/1097-0142(19940115)73:2<298::AID-CNCR2820730211>3.0.CO;2-4
P. Verrelle, M. Frederic, Y. Fonck, V. Feillel, C. Dionet, F. Kwiatkowski, R. Plagne, J. Chassagne, Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast Carcinoma Journal of the National Cancer Institute. ,vol. 83, pp. 111- 116 ,(1991) , 10.1093/JNCI/83.2.111
R Kramer, TK Weber, B Morse, R Arceci, R Staniunas, G Steele, IC Summerhayes, Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. British Journal of Cancer. ,vol. 67, pp. 959- 968 ,(1993) , 10.1038/BJC.1993.177
Stefan Duensing, Iris Dallmann, Jens Grosse, Jan Buer, Enrique Lopez Hänninen, Markus Deckert, Stephan StÖrkel, Hartmut Kirchner, Hubert Poliwoda, Jens Atzpodien, Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology. ,vol. 51, pp. 309- 313 ,(1994) , 10.1159/000227355
Ylermi Soini, Paavo Pääkkö, Kyösti Nuorva, Dia Kamel, David P. Lane, Kirsi Vähäkangas, Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Archiv. ,vol. 421, pp. 223- 228 ,(1992) , 10.1007/BF01611179
C Cordon-Cardo, J P O'Brien, J Boccia, D Casals, J R Bertino, M R Melamed, Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. Journal of Histochemistry and Cytochemistry. ,vol. 38, pp. 1277- 1287 ,(1990) , 10.1177/38.9.1974900
M. Dietel, What's new in cytostatic drug resistance and pathology. Pathology Research and Practice. ,vol. 187, pp. 892- 905 ,(1991) , 10.1016/S0344-0338(11)80589-3
K. Chin, K Ueda, I Pastan, M. Gottesman, Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. ,vol. 255, pp. 459- 462 ,(1992) , 10.1126/SCIENCE.1346476
P De Angelis, T Stokke, L Smedshammer, RA Lothe, G Lehne, Y Chen, OPF Clausen, P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo British Journal of Cancer. ,vol. 72, pp. 307- 311 ,(1995) , 10.1038/BJC.1995.329